NOVO.B.DK

456.4

-0.36%↓

GMAB.DK

1,365.5

+2.17%↑

ZEAL.DK

427.1

+1.57%↑

AMBUB.DK

103.1

-1.43%↓

NOVO.B.DK

456.4

-0.36%↓

GMAB.DK

1,365.5

+2.17%↑

ZEAL.DK

427.1

+1.57%↑

AMBUB.DK

103.1

-1.43%↓

NOVO.B.DK

456.4

-0.36%↓

GMAB.DK

1,365.5

+2.17%↑

ZEAL.DK

427.1

+1.57%↑

AMBUB.DK

103.1

-1.43%↓

NOVO.B.DK

456.4

-0.36%↓

GMAB.DK

1,365.5

+2.17%↑

ZEAL.DK

427.1

+1.57%↑

AMBUB.DK

103.1

-1.43%↓

NOVO.B.DK

456.4

-0.36%↓

GMAB.DK

1,365.5

+2.17%↑

ZEAL.DK

427.1

+1.57%↑

AMBUB.DK

103.1

-1.43%↓

Search

Coloplast A-S (Class B)

Gesloten

647.8 0.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

644

Max

651.2

Belangrijke statistieken

By Trading Economics

Inkomsten

-132M

912M

Verkoop

-96M

6.9B

K/W

Sectorgemiddelde

31.843

54.533

EPS

4.046

Dividendrendement

3.42

Winstmarge

13.16

Werknemers

16,741

EBITDA

-42M

2.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.42%

2.41%

Volgende Winsten

19 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-12B

145B

Vorige openingsprijs

647.71

Vorige sluitingsprijs

647.8

Coloplast A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2025, 23:25 UTC

Populaire aandelen

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mei 2025, 21:57 UTC

Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mei 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefónica's Operations in Uruguay

21 mei 2025, 21:01 UTC

Belangrijke Marktbewegers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mei 2025, 20:51 UTC

Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 mei 2025, 23:49 UTC

Marktinformatie

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mei 2025, 23:37 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mei 2025, 23:33 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mei 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mei 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mei 2025, 23:32 UTC

Marktinformatie
Acquisities, Fusies, Overnames

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mei 2025, 23:31 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mei 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mei 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mei 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mei 2025, 23:28 UTC

Winsten

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mei 2025, 23:27 UTC

Winsten

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mei 2025, 23:23 UTC

Acquisities, Fusies, Overnames

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mei 2025, 23:22 UTC

Acquisities, Fusies, Overnames

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mei 2025, 23:20 UTC

Acquisities, Fusies, Overnames

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mei 2025, 23:18 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mei 2025, 21:42 UTC

Top Nieuws
Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mei 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefónica's Ops in Uruguay

21 mei 2025, 21:07 UTC

Top Nieuws

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mei 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 mei 2025, 20:59 UTC

Top Nieuws

Walmart to Cut 1,500 Jobs -- WSJ

21 mei 2025, 20:52 UTC

Winsten

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Peer Vergelijking

Prijswijziging

Coloplast A-S (Class B) Prognose

Koersdoel

By TipRanks

11.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 901.38 DKK  11.86%

Hoogste 1,056 DKK

Laagste 720 DKK

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Coloplast A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

2

Buy

4

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.